Increased platelet glycogen sysnthase kinase 3beta in first-episode psychosis

Helena P G Joaquim; Marcus V Zanetti; Mauricio H Serpa; Martinus T Van de Bilt; Paulo C Sallet; Tiffany M Chaim; Geraldo F Busatto; Wagner F Gattaz; Leda L Talib

doi:10.1016/j.schres.2017.08.062

Increased platelet glycogen sysnthase kinase 3beta in first-episode psychosis

Schizophr Res. 2018 May:195:402-405. doi: 10.1016/j.schres.2017.08.062. Epub 2017 Sep 6.

Authors

Helena P G Joaquim¹, Marcus V Zanetti², Mauricio H Serpa², Martinus T Van de Bilt¹, Paulo C Sallet¹, Tiffany M Chaim³, Geraldo F Busatto³, Wagner F Gattaz⁴, Leda L Talib⁵

Affiliations

¹ Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Sao Paulo, Brazil.
² Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Sao Paulo, Brazil; Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Brazil; Laboratory of Psychiatric Neuroimaging, LIM-21, Department and Institute of Psychiatry, University of Sao Paulo, Brazil.
³ Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Brazil; Laboratory of Psychiatric Neuroimaging, LIM-21, Department and Institute of Psychiatry, University of Sao Paulo, Brazil.
⁴ Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Sao Paulo, Brazil; Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Brazil.
⁵ Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Sao Paulo, Brazil; Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), University of São Paulo, Brazil. Electronic address: leda.talib@hc.fm.usp.br.

PMID: 28888361
DOI: 10.1016/j.schres.2017.08.062

Abstract

Past studies have linked intracellular pathways related to psychotic disorders to the GSK3B enzyme. This study aimed to investigate GSK3B protein expression and phosphorylation in drug-naïve first-episode psychosis patients (n=43) at baseline and following symptom remission, and in healthy controls (n=77). At baseline GSK3B total level was higher in patients (p<0.001). In schizophrenia spectrum patients (n=25) GSK3B total and phosphorylated levels were higher than in controls and patients with other non-affective psychotic disorders (n=18) (p<0.001; p=0.027; p=0.05 respectively). No enzyme changes were found after clinical remission. The implication of this finding for the biology of psychoses warrants further studies to clarify whether increased GSK3B may be useful as a biomarker for psychosis in general, and schizophrenia in particular.

Keywords: Antipsychotic treatment; First-episode psychosis; GSK3B; Non-affective psychosis; Schizophrenia.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Female
Glycogen Synthase Kinase 3 beta / blood*
Humans
Male
Phosphorylation
Psychotic Disorders / blood*
Schizophrenia / blood*
Statistics, Nonparametric
Young Adult

Substances

GSK3B protein, human
Glycogen Synthase Kinase 3 beta